Public opinion

Americans Want FDA to End Peptide Roulette, New National Poll Finds.

A majority of Americans support legal peptide access through a U.S. pharmacy and doctor's prescription; just 3% are opposed, and nearly half remain undecided.

Peppies commissioned Mason-Dixon Polling & Strategy, one of the most-cited independent polling firms in the country, to field a national survey on what Americans actually think about peptides, legal access through licensed pharmacies, the unregulated grey market, and trust in the FDA and the pharmaceutical industry.

Topline results

Americans say adults should be able to get peptides legally, through a U.S. pharmacy with a doctor's prescription. 52% say they should, and just 3% say they should not, while 45% are not yet sure.

52%

say adults should have legal pharmacy access

say they should not

74%

back easier access to preventive treatments

60%

say the system should prioritize prevention

Download the full topline & crosstabs (PDF) → Get notified on what's next

What the poll found

Legal pharmacy access: 52% say adults should be able to obtain peptides through a licensed U.S. pharmacy with a doctor's prescription, versus just 3% who say they should not (45% not sure). 19 to 1 among those expressing an opinion (55% of adults).
Prevention over treatment: 60% say the U.S. healthcare system should prioritize preventing illness, versus 19% who say treating existing illness.
Patient outcomes first: 54% say decisions about which medications are made legal should be driven primarily by patient health outcomes, versus 6% who say pharmaceutical-industry investment.
Easier preventive access: 74% support the government making preventive treatments easier to access, even if it reduced pharmaceutical-industry revenue.
Trust in the FDA: just 37% say they have a great deal or a fair amount of trust in the FDA to put the public's interest ahead of the pharmaceutical industry; roughly 6 in 10 say "not much" or "none."
Awareness, not opposition, is the gap: 49% of adults say they have heard nothing at all about peptides, and only 5% report that anyone in their household has used a compounded peptide, roughly 13 million U.S. adults.

Methodology

Firm: Mason-Dixon Polling & Strategy, Inc., of Jacksonville, Florida, commissioned and paid for by Peppies, LLC.
Sample: 1,000 adults nationwide, interviewed by telephone, randomly selected from a nationwide voter-registration list that included both landlines and mobile phones.
Quotas: Assigned to reflect adult population by state.
Margin of error: No more than ±3.2 percentage points at the 95% confidence level; higher for any subgroup.
Field dates: July 13 through July 16, 2026.
Full data: The complete topline and crosstabs (by region, gender, age, race, and party) are in the downloadable PDF.

For journalists. The full topline and crosstabs are free to use with attribution to Mason-Dixon Polling & Strategy. For the questionnaire, additional breakouts, or an interview, contact press@peppies.com. Peppies commissioned and paid for the survey, is independent, and does not sell peptides.